KR102215272B1 - 비정형 단백질 키나제 c의 아자퀴나졸린 억제제 - Google Patents
비정형 단백질 키나제 c의 아자퀴나졸린 억제제 Download PDFInfo
- Publication number
- KR102215272B1 KR102215272B1 KR1020157010868A KR20157010868A KR102215272B1 KR 102215272 B1 KR102215272 B1 KR 102215272B1 KR 1020157010868 A KR1020157010868 A KR 1020157010868A KR 20157010868 A KR20157010868 A KR 20157010868A KR 102215272 B1 KR102215272 B1 KR 102215272B1
- Authority
- KR
- South Korea
- Prior art keywords
- optionally substituted
- pyridin
- pyrido
- cyclopropyl
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(C)C(C)C(C(C)C*C)(C1*(C)CCC1)C(CCC(C*)*C)(C(C)CC)C(C)C1(CC)*C1 Chemical compound CCC(C)C(C)C(C(C)C*C)(C1*(C)CCC1)C(CCC(C*)*C)(C(C)CC)C(C)C1(CC)*C1 0.000 description 4
- XIALRQNUNYOSJP-UHFFFAOYSA-N O=C1NC(Cl)=Nc2c1ccnc2 Chemical compound O=C1NC(Cl)=Nc2c1ccnc2 XIALRQNUNYOSJP-UHFFFAOYSA-N 0.000 description 2
- OWMJNAKVBMQCTE-UHFFFAOYSA-N C(C1)C1c1cncc(N=C(c2ccncc2)N2)c1C2N1CCNCC1 Chemical compound C(C1)C1c1cncc(N=C(c2ccncc2)N2)c1C2N1CCNCC1 OWMJNAKVBMQCTE-UHFFFAOYSA-N 0.000 description 1
- CNQRGLZNEAHZGB-UHFFFAOYSA-N C(C1)C1c1cncc2c1c(N1CCNCC1)nc(-c1ccncc1-c1ccccc1)n2 Chemical compound C(C1)C1c1cncc2c1c(N1CCNCC1)nc(-c1ccncc1-c1ccccc1)n2 CNQRGLZNEAHZGB-UHFFFAOYSA-N 0.000 description 1
- UKPUNBVRSGOLQI-GFCCVEGCSA-N C(CNC1)[C@H]1Nc1nc(N2CCOCC2)nc2c1ccnc2-c1ccn[nH]1 Chemical compound C(CNC1)[C@H]1Nc1nc(N2CCOCC2)nc2c1ccnc2-c1ccn[nH]1 UKPUNBVRSGOLQI-GFCCVEGCSA-N 0.000 description 1
- PBNYTXGNAJMNBN-UEPDSTOUSA-N C/C=C\C(\C)=C(/C)\C1N(C)C1 Chemical compound C/C=C\C(\C)=C(/C)\C1N(C)C1 PBNYTXGNAJMNBN-UEPDSTOUSA-N 0.000 description 1
- JRXXEEXVXFHECN-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1NC(c2ccncc2)=Nc2cncc(C3CC3)c12)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1NC(c2ccncc2)=Nc2cncc(C3CC3)c12)=O JRXXEEXVXFHECN-UHFFFAOYSA-N 0.000 description 1
- RTMAACQLJFALSF-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1nc(-c2ccnc(Cl)c2)nc2c1c(Cl)cnc2)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1nc(-c2ccnc(Cl)c2)nc2c1c(Cl)cnc2)=O RTMAACQLJFALSF-UHFFFAOYSA-N 0.000 description 1
- NCVZUVPQLZIKGT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1nc(C2=CCN(C)C(Nc(cccc3)c3F)=C2)nc2c1c(Cl)cnc2)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1nc(C2=CCN(C)C(Nc(cccc3)c3F)=C2)nc2c1c(Cl)cnc2)=O NCVZUVPQLZIKGT-UHFFFAOYSA-N 0.000 description 1
- GCAOXQMLXSSTAF-CYBMUJFWSA-N CC(C)(C)OC(N(CC1)C[C@@H]1Nc1nc(N2CCOCC2)nc2c1ccnc2Cl)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@@H]1Nc1nc(N2CCOCC2)nc2c1ccnc2Cl)=O GCAOXQMLXSSTAF-CYBMUJFWSA-N 0.000 description 1
- DCVUXVIIIGLLNG-MRVPVSSYSA-N CC(C)(C)OC(N(CC1)C[C@H](CO2)N1S2(=O)=O)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@H](CO2)N1S2(=O)=O)=O DCVUXVIIIGLLNG-MRVPVSSYSA-N 0.000 description 1
- ZSYWEVWBRTYHHV-UHFFFAOYSA-N CC1(C)OB(c2c(cc(Cc(cccc3)c3F)[n]3S(c4ccccc4)(=O)=O)c3ncc2)OC1(C)C Chemical compound CC1(C)OB(c2c(cc(Cc(cccc3)c3F)[n]3S(c4ccccc4)(=O)=O)c3ncc2)OC1(C)C ZSYWEVWBRTYHHV-UHFFFAOYSA-N 0.000 description 1
- DULZVFFGUXLRSB-UHFFFAOYSA-N CCC1(C)NC1 Chemical compound CCC1(C)NC1 DULZVFFGUXLRSB-UHFFFAOYSA-N 0.000 description 1
- FVIWGIYGBZLZSG-UHFFFAOYSA-N CCC1NC1C Chemical compound CCC1NC1C FVIWGIYGBZLZSG-UHFFFAOYSA-N 0.000 description 1
- DRUOYXQMVSLHAR-UHFFFAOYSA-N CCN1C(C)C1 Chemical compound CCN1C(C)C1 DRUOYXQMVSLHAR-UHFFFAOYSA-N 0.000 description 1
- ZYJCTOLZHAXVCQ-UHFFFAOYSA-N CCOC(c(cc(nc1)Cl)c1N)=O Chemical compound CCOC(c(cc(nc1)Cl)c1N)=O ZYJCTOLZHAXVCQ-UHFFFAOYSA-N 0.000 description 1
- MIVZAELFSMQDQH-UHFFFAOYSA-N COc1cncc(N)c1C(N)=O Chemical compound COc1cncc(N)c1C(N)=O MIVZAELFSMQDQH-UHFFFAOYSA-N 0.000 description 1
- MVSBFHLTTZJKFL-UHFFFAOYSA-N COc1cncc2c1c(O)nc(-c1ccnc(Cl)c1)n2 Chemical compound COc1cncc2c1c(O)nc(-c1ccnc(Cl)c1)n2 MVSBFHLTTZJKFL-UHFFFAOYSA-N 0.000 description 1
- POAUMNOKVCARFY-SNVBAGLBSA-N Fc(cc1)ccc1OC[C@@H]1NCCNC1 Chemical compound Fc(cc1)ccc1OC[C@@H]1NCCNC1 POAUMNOKVCARFY-SNVBAGLBSA-N 0.000 description 1
- QXQPGYURJJBELR-UHFFFAOYSA-N N=C(NC(c1c(C2CC2)cncc1F)=O)N1CCOCC1 Chemical compound N=C(NC(c1c(C2CC2)cncc1F)=O)N1CCOCC1 QXQPGYURJJBELR-UHFFFAOYSA-N 0.000 description 1
- BPHCSRXTRKZVDY-UHFFFAOYSA-N O=C1NC(S)=Nc2cnccc12 Chemical compound O=C1NC(S)=Nc2cnccc12 BPHCSRXTRKZVDY-UHFFFAOYSA-N 0.000 description 1
- YCUXRICMRLTMBL-UHFFFAOYSA-N O=S(c1ccccc1)([n]1c2nccc(Br)c2cc1Cc(cccc1)c1F)=O Chemical compound O=S(c1ccccc1)([n]1c2nccc(Br)c2cc1Cc(cccc1)c1F)=O YCUXRICMRLTMBL-UHFFFAOYSA-N 0.000 description 1
- MFWBDVJINSDHBX-UHFFFAOYSA-N OC(c1c(C2CC2)cncc1F)=O Chemical compound OC(c1c(C2CC2)cncc1F)=O MFWBDVJINSDHBX-UHFFFAOYSA-N 0.000 description 1
- MIOVVIKQRTYGJQ-UHFFFAOYSA-N Oc1nc(-c2ccncc2)nc(cn2)c1cc2Cl Chemical compound Oc1nc(-c2ccncc2)nc(cn2)c1cc2Cl MIOVVIKQRTYGJQ-UHFFFAOYSA-N 0.000 description 1
- ORNSPJMGCZJVQO-UHFFFAOYSA-N Oc1nc(-c2ccncc2)nc2c1c(C1CC1)cnc2 Chemical compound Oc1nc(-c2ccncc2)nc2c1c(C1CC1)cnc2 ORNSPJMGCZJVQO-UHFFFAOYSA-N 0.000 description 1
- MIOBVOSVEKIRBO-UHFFFAOYSA-N Oc1nc(N2CC(Cc3ccccc3)OCC2)nc2c1ccnc2 Chemical compound Oc1nc(N2CC(Cc3ccccc3)OCC2)nc2c1ccnc2 MIOBVOSVEKIRBO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261707340P | 2012-09-28 | 2012-09-28 | |
| US61/707,340 | 2012-09-28 | ||
| US201361781364P | 2013-03-14 | 2013-03-14 | |
| US61/781,364 | 2013-03-14 | ||
| PCT/US2013/062085 WO2014052699A1 (en) | 2012-09-28 | 2013-09-27 | Azaquinazoline inhibitors of atypical protein kinase c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150086248A KR20150086248A (ko) | 2015-07-27 |
| KR102215272B1 true KR102215272B1 (ko) | 2021-02-15 |
Family
ID=49326872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157010868A Active KR102215272B1 (ko) | 2012-09-28 | 2013-09-27 | 비정형 단백질 키나제 c의 아자퀴나졸린 억제제 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9914730B2 (https=) |
| EP (1) | EP2900666B1 (https=) |
| JP (1) | JP6535430B2 (https=) |
| KR (1) | KR102215272B1 (https=) |
| CN (1) | CN105102456B (https=) |
| AU (1) | AU2013323360B2 (https=) |
| BR (1) | BR112015007061B1 (https=) |
| CA (1) | CA2886495C (https=) |
| CL (1) | CL2015000781A1 (https=) |
| EA (1) | EA030253B1 (https=) |
| IL (1) | IL237918B (https=) |
| MX (1) | MX372736B (https=) |
| NZ (1) | NZ706857A (https=) |
| PH (1) | PH12015500689A1 (https=) |
| SG (1) | SG11201502301YA (https=) |
| TW (1) | TWI663165B (https=) |
| WO (1) | WO2014052699A1 (https=) |
| ZA (1) | ZA201502783B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9914730B2 (en) * | 2012-09-28 | 2018-03-13 | Cancer Research Technology Limited | Azaquinazoline inhibitors of Atypical protein Kinase C |
| WO2014100501A1 (en) | 2012-12-20 | 2014-06-26 | Sanford-Burnham Medical Research Institute | Small molecule agonists of neurotensin receptor 1 |
| PE20151727A1 (es) | 2013-03-14 | 2015-12-17 | Boehringer Ingelheim Int | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c |
| AU2014308616B2 (en) | 2013-08-23 | 2018-12-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| WO2015143376A1 (en) * | 2014-03-21 | 2015-09-24 | Nivalis Therapeutics, Inc. | Novel compounds for the treatment of cystic fibrosis |
| TWI675836B (zh) * | 2014-03-25 | 2019-11-01 | 美商伊格尼塔公司 | 非典型蛋白質激酶ｃ之氮雜喹唑啉抑制劑 |
| JP6599908B2 (ja) | 2014-06-25 | 2019-10-30 | サンフォード−バーンハム メディカル リサーチ インスティテュート | ニューロテンシン受容体１の小分子アゴニスト |
| TW201613919A (en) | 2014-07-02 | 2016-04-16 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
| WO2016037106A1 (en) * | 2014-09-05 | 2016-03-10 | Allosteros Therapeutics, Inc | CaMKII INHIBITORS AND USES THEREOF |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| NZ730475A (en) * | 2014-10-29 | 2018-09-28 | Dong A St Co Ltd | Novel pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (kdms) |
| CN105288512A (zh) * | 2015-12-08 | 2016-02-03 | 李野林 | 一种治疗肥胖症的中药组合物 |
| CA3026211A1 (en) | 2016-06-13 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
| CN109843858B (zh) * | 2016-08-15 | 2023-05-05 | 润新生物公司 | 某些化学实体、组合物及方法 |
| AU2017312970B2 (en) * | 2016-08-16 | 2021-08-12 | Merck Patent Gmbh | 2-oxo-imidazopyridines as reversible BTK inhibitors and uses thereof |
| AU2017329090B9 (en) | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| JOP20190257A1 (ar) | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
| ES2952265T3 (es) | 2017-05-02 | 2023-10-30 | Novartis Ag | Terapia combinada que comprende un inhibidor de Raf y trametinib |
| WO2019000682A1 (zh) | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| CN110582489B (zh) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
| US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
| MX2021000966A (es) * | 2018-07-25 | 2021-07-06 | Faes Farma Sa | Piridopirimidinas como inhibidores del receptor de histamina h4. |
| US20210347785A1 (en) * | 2018-08-01 | 2021-11-11 | Shanghai Ennovabio Pharmaceuticals Co., Ltd. | Preparation and application of aromatic compound having immunoregulatory function |
| CN111100063B (zh) * | 2018-10-25 | 2022-05-17 | 南京药石科技股份有限公司 | 一种合成2-氟甲基取代的吡咯烷、哌啶以及哌嗪衍生物的制备方法 |
| US20220143028A1 (en) * | 2019-03-28 | 2022-05-12 | Cancer Research Technology Ltd | Inhibitors of atypical protein kinase c and their use in treating hedgehog pathway-dependent cancers |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| CN116120243B (zh) * | 2021-11-15 | 2025-07-29 | 都创(上海)医药科技股份有限公司 | aPKC抑制剂化合物中间体片段及其制备方法和应用 |
| CN114349711B (zh) * | 2022-02-28 | 2023-08-15 | 四川依维欣医药科技有限公司 | 一种（R）-1-Boc-3-羟甲基哌嗪的合成方法 |
| CN117088898B (zh) * | 2022-05-13 | 2026-02-06 | 中国药科大学 | 稠环嘧啶类化合物及其制备方法、药物组合物和应用 |
| CN120882714A (zh) * | 2022-12-13 | 2025-10-31 | 风树疗法公司 | {5-环丙基-2-[2-(3,6-二氟-吡啶-2-基氨基)-吡啶-4-基]-吡啶并[3,4-d]嘧啶-4-基}-((s)-3,3-二甲基-哌啶-4-基)-胺的固体形式 |
| CN117343005A (zh) * | 2023-10-08 | 2024-01-05 | 上海泰坦科技股份有限公司 | 一种异烟酸衍生物的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050038047A1 (en) | 2003-08-14 | 2005-02-17 | Edwards Paul John | Azaquinazoline derivatives |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4936700A (https=) | 1972-08-16 | 1974-04-05 | ||
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| JP2002080423A (ja) * | 2000-09-06 | 2002-03-19 | Daikin Ind Ltd | トリフルオロ酢酸エチルの合成方法 |
| EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1610774A4 (en) * | 2003-04-09 | 2008-07-16 | Exelixis Inc | TIE-2 MODULATORS AND METHODS OF USE |
| US7582631B2 (en) * | 2004-01-14 | 2009-09-01 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| AU2006217744A1 (en) * | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | 2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors |
| KR101438245B1 (ko) * | 2006-08-23 | 2014-09-04 | 쿠도스 파마슈티칼스 리미티드 | Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체 |
| BRPI0716880A2 (pt) * | 2006-09-08 | 2013-10-15 | Pfizer Prod Inc | Síntese de 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| EP2473054B1 (en) * | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
| US9914730B2 (en) * | 2012-09-28 | 2018-03-13 | Cancer Research Technology Limited | Azaquinazoline inhibitors of Atypical protein Kinase C |
| KR20150130389A (ko) * | 2013-03-13 | 2015-11-23 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 티에노피리미딘 및 티에노피리딘 화합물을 포함하는 조성물 및 이의 사용 방법 |
| WO2016040330A1 (en) * | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| AU2016378579A1 (en) * | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
-
2013
- 2013-09-27 US US14/038,915 patent/US9914730B2/en not_active Expired - Fee Related
- 2013-09-27 SG SG11201502301YA patent/SG11201502301YA/en unknown
- 2013-09-27 EA EA201590661A patent/EA030253B1/ru not_active IP Right Cessation
- 2013-09-27 KR KR1020157010868A patent/KR102215272B1/ko active Active
- 2013-09-27 MX MX2015004016A patent/MX372736B/es active IP Right Grant
- 2013-09-27 TW TW102134928A patent/TWI663165B/zh active
- 2013-09-27 AU AU2013323360A patent/AU2013323360B2/en not_active Ceased
- 2013-09-27 EP EP13774578.2A patent/EP2900666B1/en active Active
- 2013-09-27 BR BR112015007061-2A patent/BR112015007061B1/pt active IP Right Grant
- 2013-09-27 NZ NZ706857A patent/NZ706857A/en unknown
- 2013-09-27 WO PCT/US2013/062085 patent/WO2014052699A1/en not_active Ceased
- 2013-09-27 CA CA2886495A patent/CA2886495C/en active Active
- 2013-09-27 CN CN201380062263.9A patent/CN105102456B/zh active Active
- 2013-09-27 JP JP2015534689A patent/JP6535430B2/ja active Active
-
2015
- 2015-03-24 IL IL237918A patent/IL237918B/en active IP Right Grant
- 2015-03-26 PH PH12015500689A patent/PH12015500689A1/en unknown
- 2015-03-27 CL CL2015000781A patent/CL2015000781A1/es unknown
- 2015-04-23 ZA ZA2015/02783A patent/ZA201502783B/en unknown
- 2015-12-18 US US14/975,605 patent/US9896446B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050038047A1 (en) | 2003-08-14 | 2005-02-17 | Edwards Paul John | Azaquinazoline derivatives |
Non-Patent Citations (1)
| Title |
|---|
| Bioorganic & Medicinal Chemistry Letters, Vol.21, pp.7367-7372 (2011) 1부.* |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102215272B1 (ko) | 비정형 단백질 키나제 c의 아자퀴나졸린 억제제 | |
| KR101926245B1 (ko) | Ｔａｎｋ-결합 키나제 억제제 화합물 | |
| JP6613245B2 (ja) | 非定型プロテインキナーゼｃのアザキナゾリン阻害薬 | |
| KR20190076976A (ko) | Ret 키나제 억제제로서의 치환된 피라졸로[1,5-a]피리딘 화합물 | |
| EP3053923B1 (en) | Triazolopyrazine derivatives as tyrosin kinase inhibitors | |
| CN110036012A (zh) | 吡啶并[3,4-d]嘧啶衍生物及其药学上可接受的盐 | |
| AU2026200481A1 (en) | 4-(Imidazo[1,2-a]pyridin-3-yl)-pyrimidine derivatives | |
| EP4069369A1 (en) | Cyclic compounds and methods of using same | |
| HK1211928B (en) | Azaquinazoline inhibitors of atypical protein kinase c | |
| HK1212336B (en) | Azaquinazoline inhibitors of atypical protein kinase c | |
| WO2025008061A1 (en) | 1,6-naphthridine compounds as smarca2 inhibitors useful for the treatment of smarca4 deficient cancers | |
| HK1236197A1 (en) | Tank-binding kinase inhibitor compounds | |
| HK1236197B (en) | Tank-binding kinase inhibitor compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150427 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20180927 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20200120 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20200910 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20210205 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20210208 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20240320 Start annual number: 4 End annual number: 4 |